Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 12:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,101 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Fed Clear all
Recruiting Phase 2 Interventional

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

NCT06906341
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms, Endometrial Cancer
Interventions
Relacorilant 150 mg once daily (QD), Nab-paclitaxel 80 mg/m^2, Bevacizumab 10 mg/kg
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
16
States / cities
Birmingham, Alabama • Palo Alto, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 17, 2026, 12:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effect of Oral Belumosudil on Inhibition of Various Proteins in the Fed State in Healthy Male Subjects

NCT05806567
View directory record Official record
Conditions
Immune System Disorder, Healthy Volunteers
Interventions
Belumosudil, UGT1A1 victim drug, P-gp victim drug, OATP1B1/BCRP victim drug
Drug
Lead sponsor
Kadmon, a Sanofi Company
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 17, 2026, 12:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Amlodipine Tablets Under Fed Conditions

NCT00601302
View directory record Official record
Conditions
Hypertension, Chronic Stable Angina, Vasospastic Angina
Interventions
Amlodipine
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 17, 2026, 12:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioequivalence Study of Advil Dual Action Liquid Filled Capsules (125 mg/250 mg) Versus Advil Dual Action Caplets (125 mg/250 mg) and Bioavailability Assessment of Advil Dual Action Liquid Filled Capsules (125 mg/250 mg) and Advil Liqui-Gels (200 mg) in Healthy Adult Subjects

NCT06802185
View directory record Official record
Conditions
Pain
Interventions
ADA Liquid Filled Capsules (Test Product), ADA Caplets (Reference Product), Advil Liqui-gels (Reference Product)
Drug
Lead sponsor
HALEON
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Oct 17, 2026, 12:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Food on LOXO-783 in Healthy Participants

NCT06028425
View directory record Official record
Conditions
Healthy
Interventions
LOXO-783
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced Oct 17, 2026, 12:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Food on the Pharmacokinetics (PK) of Emraclidine in Healthy Adult Participants

NCT05915546
View directory record Official record
Conditions
Healthy
Interventions
Emraclidine
Drug
Lead sponsor
Cerevel Therapeutics, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Dilworth, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 24, 2023 · Synced Oct 17, 2026, 12:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Single and Multiple Escalating Doses of Aramchol Administered Under Fed Conditions in Healthy Chinese Volunteers

NCT02803996
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Aramchol, Placebo
Drug
Lead sponsor
Galmed Pharmaceuticals Ltd
Industry
Eligibility
18 Years to 50 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Dec 21, 2016 · Synced Oct 17, 2026, 12:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability of Tablet Formulations of GSK2248761 in Healthy Adult Subjects. SGN114435

NCT01209117
View directory record Official record
Conditions
Infections, Human Immunodeficiency Virus and Herpesviridae, Infection, Human Immunodeficiency Virus
Interventions
GSK2248761 WBM Capsule, GSK2248761 WBM Tablet Formulation 1, GSK2248761 WBM Tablet Formulation 2, GSK2248761 WBM Tablet Formulation 3, GSK2248761 WBM Tablet
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Oct 17, 2026, 12:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of the Potential Impact of a High-fat Meal on the Pharmacokinetics of CRS3123 in Healthy Adult Participants

NCT06988423
View directory record Official record
Conditions
Food Effect in Healthy Participants
Interventions
CRS3123 200 mg capsule
Drug
Lead sponsor
Crestone, Inc
Industry
Eligibility
18 Years to 64 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 17, 2026, 12:23 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Growth and Tolerance of Hypoallergenic Formulas

NCT01354366
View directory record Official record
Conditions
Growth of Term Infants
Interventions
Infant formula
Other
Lead sponsor
Mead Johnson Nutrition
Industry
Eligibility
12 Days to 16 Days
Enrollment
511 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
24
States / cities
Birmingham, Alabama • Dothan, Alabama • Pinson, Alabama + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2013 · Synced Oct 17, 2026, 12:23 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

The Objective of This Phase 1 Study is to Evaluate the Food Effect of 100 mg Hezkue Turbo® (ASP-001.1, Sildenafil) Under Fed Versus 100 mg of Hezkue Turbo® (ASP-001.1, Sildenafil) Under Fasted Conditions in Healthy Adult Male Subjects

NCT06872866
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
ASP-001.1, ASP-001.1
Drug · Device
Lead sponsor
Aspargo Labs, Inc
Industry
Eligibility
20 Years to 70 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Oct 17, 2026, 12:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety and Tolerability of E2511 in Healthy Participants

NCT04547361
View directory record Official record
Conditions
Healthy Volunteers
Interventions
E2511, E2511 Matched Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Oct 17, 2026, 12:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of Cebranopadol

NCT03882762
View directory record Official record
Conditions
Pharmacokinetic
Interventions
Cebranopadol 200 μg tablet
Drug
Lead sponsor
Tris Pharma, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Oct 17, 2026, 12:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety, Drug Levels, Food and Relative Bioavailability of BMS-986365 in Healthy Adult Male Participants

NCT06417229
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986365, Rabeprazole
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 17, 2026, 12:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability and Impact of Rabeprazole for PF-07799933, Food-Effect for PF-07799933 and PF-07799544

NCT07563894
View directory record Official record
Conditions
Healthy
Interventions
PF-07799933 tablets with PF-07799544 fasted, PF-07799933 film-coated tablets with PF-07799544 fasted, PF-07799933 film-coated tablets with PF-07799544 fed, PF-07799933 film-coated tablets fasted, PF-07799933 film-coated tablets following rabeprazole pretreatment fasted
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 17, 2026, 12:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Determine the Fed Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets

NCT01099709
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Reformulated OXY (oxycodone HCl), Original OxyContin® (OXY) (oxycodone HCl)
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years to 50 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated May 6, 2010 · Synced Oct 17, 2026, 12:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-Label Food Effect Study of Telotristat Etiprate

NCT02157584
View directory record Official record
Conditions
Healthy
Interventions
Telotristat etiprate
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Oct 17, 2026, 12:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Assessment of Growth of Infants Fed a New Formula

NCT00937014
View directory record Official record
Conditions
Infant Nutrition
Interventions
standard infant formula, Test formula
Other
Lead sponsor
Société des Produits Nestlé (SPN)
Industry
Eligibility
11 Days to 17 Days
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
3
States / cities
Newburgh, Indiana • Owensboro, Kentucky • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Oct 17, 2026, 12:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Study of Doxycycline Monohydrate Tablets 100 mg and Adoxa Tablets 100 mg

NCT00648180
View directory record Official record
Conditions
Healthy
Interventions
Doxycycline Monohydrate Tablets 100 mg, Adoxa Tablets 100 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 17, 2026, 12:23 AM EDT
Withdrawn No phase listed Observational

Review of Enteral Formulas in Children

NCT04247269
View directory record Official record
Conditions
Enteral Feeding Intolerance, Tube Feeding, Nutrition Disorder, Child
Interventions
Enteral Tube Feeding
Other
Lead sponsor
Société des Produits Nestlé (SPN)
Industry
Eligibility
1 Year to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Oct 17, 2026, 12:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Adherence of 2 Strengths of Newly Manufactured Samples and Aged Samples of a New Formulation (JNJ-35685-AAA-G016 and JNJ-35685-AAA-G021) of Fentanyl Transdermal System Compared With Duragesic Fentanyl Transdermal Patch in Healthy Participants

NCT02608320
View directory record Official record
Conditions
Healthy
Interventions
Duragesic (Fentanyl Transdermal System [TDS] Small Patches), New JNJ-35685-AAA-G016 (Fentanyl TDS -Small Patches), Aged JNJ-35685-AAA-G016 (Fentanyl TDS Small Patches), Duragesic (Fentanyl TDS Large Patches), New JNJ-35685-AAA-G021 (Fentanyl TDS Large Patches), Aged JNJ-35685-AAA-G021 (Fentanyl TDS Large Patches)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 17, 2026, 12:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LY2801653 in Healthy Participants Who Are Not Able to Have Children

NCT02370485
View directory record Official record
Conditions
Healthy
Interventions
LY2801653
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jun 19, 2015 · Synced Oct 17, 2026, 12:23 AM EDT
Completed Not applicable Interventional

Effect of Vitamin D in Diets of Preterm Infants

NCT01698840
View directory record Official record
Conditions
Premature Infants
Interventions
Vitamin D, Placebo
Dietary Supplement
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 17, 2026, 12:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Relative Bioavailability and Food Effect of ABBV-668 Extended-Release Formulations in Adult Participants

NCT06477926
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ABBV-668 IR, ABBV-668 ER
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 17, 2026, 12:23 AM EDT